Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin filed Amendment No. 4 to their Schedule 13G with the SEC on November 16, 2026, disclosing a combined beneficial ownership position in Nurix Therapeutics, Inc. common stock as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: Each of the three reporting persons beneficially owns 6,000,000 shares of Nurix Therapeutics common stock.
- Percent of class: The 6,000,000 shares represent 5.49% of Nurix Therapeutics common stock outstanding.
- Voting and dispositive power: All 6,000,000 shares are held with shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as 0.
- Shares outstanding basis: The percentage was calculated using 109,249,814 shares of common stock outstanding as of September 30, 2026.
- Control relationship: According to the filing, Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
- Filing trigger date: The event requiring this amendment occurred on September 30, 2026.
Deep Track Capital's Amended Ownership Position in Nurix Therapeutics
The Schedule 13G Amendment No. 4 was filed jointly by three reporting persons: Deep Track Capital, LP, a Delaware limited partnership based in Greenwich, Connecticut; Deep Track Biotechnology Master Fund, Ltd., a Cayman Islands corporation; and David Kroin, a United States citizen. According to the filing, David Kroin signed on behalf of all three entities, serving as Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP, and as Director of Deep Track Biotechnology Master Fund, Ltd.
Nurix Therapeutics, Inc. is a biopharmaceutical company headquartered at 1600 Sierra Point Parkway, Brisbane, CA 94005, according to the issuer address provided in the filing. The securities covered by this statement are shares of common stock with a par value of $0.001 per share, identified by CUSIP number 67080M103. The filing states that the total shares outstanding used to compute the 5.49% ownership figure, 109,249,814, was drawn from Nurix Therapeutics' quarterly report filed with the SEC on October 13, 2026.
The filing's certifications state that the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11." The three parties also submitted a Joint Filing Statement pursuant to Rule 13d-1(k), confirming joint responsibility for the Schedule 13G and all subsequent amendments.
What Was Disclosed
Three affiliated reporting persons, Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin, disclosed a shared beneficial ownership of 6,000,000 shares, equal to 5.49% of Nurix Therapeutics common stock, as of September 30, 2026, in this Amendment No. 4 to Schedule 13G.



Please wait processing your request...